Study title: Open-label 40 weeks extension of study S-12159 to follow-up the long-term tolerability and efficacy of tenoxicam in children and adolescents suffering from juvenile rheumatoid arthritis (JRA) treated for up to one year.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Musculoskeletal Diseases [C05] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: TENOXICAM | |||||
| ATC code: M01AC02 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: S-12161 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |